Fiche publication
Date publication
octobre 2024
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
,
Pr PESSAUX Patrick
,
Dr VERRIER Eloi
Tous les auteurs :
Taverniti V, Meiss-Heydmann L, Gadenne C, Vanrusselt H, Kum DB, Giannone F, Pessaux P, Schuster C, Baumert TF, Debing Y, Verrier ER
Lien Pubmed
Résumé
Chronic HBV infection is the leading cause of liver disease and of hepatocellular carcinoma. The improvement of antiviral therapy remains an unmet medical need. Capsid assembly modulators (CAMs) target the HBV core antigen (HBc) and inhibit HBV replication. Although CAM-A compounds are well-known inducers of aberrant viral capsid aggregates, their mechanisms of action in HBV-hepatocyte interactions are poorly understood. Recently, we demonstrated that CAM-A molecules lead to a sustained reduction of HBsAg in the serum of HBV replicating mice and induce HBc aggregation in the nucleus of HBc-expressing cells leading to cell death.
Mots clés
ANXA1, Annexin A1, Apoptosis, Capsid assembly modulators, Hepatitis B virus, Lipocortin I
Référence
JHEP Rep. 2024 10;6(10):101134
